AU2013355391B2 - Peptide compounds and methods of production and use thereof - Google Patents

Peptide compounds and methods of production and use thereof Download PDF

Info

Publication number
AU2013355391B2
AU2013355391B2 AU2013355391A AU2013355391A AU2013355391B2 AU 2013355391 B2 AU2013355391 B2 AU 2013355391B2 AU 2013355391 A AU2013355391 A AU 2013355391A AU 2013355391 A AU2013355391 A AU 2013355391A AU 2013355391 B2 AU2013355391 B2 AU 2013355391B2
Authority
AU
Australia
Prior art keywords
seq
peptide
cap37
composition
wound
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2013355391A
Other languages
English (en)
Other versions
AU2013355391A1 (en
Inventor
Gina L. Griffith
Anne Kasus-Jacobi
H. Anne Pereira
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Oklahoma
Original Assignee
University of Oklahoma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Oklahoma filed Critical University of Oklahoma
Publication of AU2013355391A1 publication Critical patent/AU2013355391A1/en
Application granted granted Critical
Publication of AU2013355391B2 publication Critical patent/AU2013355391B2/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5383—1,4-Oxazines, e.g. morpholine ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/542—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/545—Compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins, cefaclor, or cephalexine
    • A61K31/546—Compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins, cefaclor, or cephalexine containing further heterocyclic rings, e.g. cephalothin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/14—Peptides containing saccharide radicals; Derivatives thereof, e.g. bleomycin, phleomycin, muramylpeptides or vancomycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A61K38/1729—Cationic antimicrobial peptides, e.g. defensins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Transplantation (AREA)
  • Dermatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AU2013355391A 2012-12-03 2013-12-03 Peptide compounds and methods of production and use thereof Active AU2013355391B2 (en)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US201261732750P 2012-12-03 2012-12-03
US61/732,750 2012-12-03
US201361812584P 2013-04-16 2013-04-16
US61/812,584 2013-04-16
US201361813527P 2013-04-18 2013-04-18
US61/813,527 2013-04-18
PCT/US2013/072884 WO2014089088A1 (en) 2012-12-03 2013-12-03 Peptide compounds and methods of production and use thereof

Publications (2)

Publication Number Publication Date
AU2013355391A1 AU2013355391A1 (en) 2015-07-23
AU2013355391B2 true AU2013355391B2 (en) 2017-08-03

Family

ID=50883940

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2013355391A Active AU2013355391B2 (en) 2012-12-03 2013-12-03 Peptide compounds and methods of production and use thereof

Country Status (7)

Country Link
US (2) US9603896B2 (cg-RX-API-DMAC7.html)
EP (1) EP2925341B1 (cg-RX-API-DMAC7.html)
JP (1) JP6377070B2 (cg-RX-API-DMAC7.html)
AU (1) AU2013355391B2 (cg-RX-API-DMAC7.html)
CA (1) CA2893504C (cg-RX-API-DMAC7.html)
DK (1) DK2925341T3 (cg-RX-API-DMAC7.html)
WO (1) WO2014089088A1 (cg-RX-API-DMAC7.html)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9096679B2 (en) 2012-12-03 2015-08-04 The Board Of Regents Of The University Of Oklahoma Peptide compounds and methods of production and use thereof
JP6405365B2 (ja) 2013-04-16 2018-10-17 ザ ボード オブ リージェンツ オブ ザ ユニヴァーシティ オブ オクラホマ ペプチド化合物及びその製造方法及びその使用
US20200157159A1 (en) 2013-04-16 2020-05-21 The Board Of Regents Of The University Of Oklahoma Peptide compounds and compositions thereof
CN106397456B (zh) * 2016-08-31 2019-05-07 成都倍特药业有限公司 一种含高纯度头孢地尼的组合物及其精制方法
EP3802568A4 (en) 2018-06-08 2022-07-13 The Board of Regents of the University of Oklahoma PEPTIDE THERAPEUTICS USED TO TREAT ALZHEIMER'S DISEASE AND RELATED DISEASES
CN117586376A (zh) * 2022-08-10 2024-02-23 成都奥达生物科技有限公司 一种长效胰岛素化合物

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5627262A (en) 1989-07-05 1997-05-06 The Board Of Regents Of The University Of Oklahoma Method and composition for the treatment of septic shock
US6503881B2 (en) * 1996-08-21 2003-01-07 Micrologix Biotech Inc. Compositions and methods for treating infections using cationic peptides alone or in combination with antibiotics
US6107460A (en) 1999-03-01 2000-08-22 The Board Of Regents Of The University Of Oklahoma Antimicrobial peptides and methods of use thereof
WO2002042259A2 (en) * 2000-11-27 2002-05-30 University Of Maryland, Baltimore Methods of synthesizing and using derivatives of [2-(2-aminoethoxy)ethoxy] acetic acid
AU2002305845B2 (en) * 2001-06-08 2006-03-30 Ipsen Pharma S.A.S. Somatostatin-dopamine chimeric analogs
US7655480B2 (en) 2002-03-08 2010-02-02 The Board Of Regents Of The University Of Oklahoma Method for predicting sepsis or an acute infectious inflammatory response
US8450071B2 (en) 2002-03-08 2013-05-28 The Board Of Regents Of The University Of Oklahoma Biomarker and method for detecting a chronic inflammatory-associated disease
AU2003220034A1 (en) 2002-03-08 2003-09-22 Heloise, Anne, Pereira, Ph. D. An early detection marker for chronic inflammatory associated diseases
US7354900B2 (en) * 2002-05-03 2008-04-08 The Board Of Regents Of The University Of Oklahoma Treatment and inhibition of ocular infections and wounds by CAP37 and CAP37 peptides
CN101027318B (zh) 2004-07-19 2016-05-25 比奥孔有限公司 胰岛素-低聚物共轭物,制剂及其用途
CN101300022A (zh) 2005-08-01 2008-11-05 俄克拉荷马州大学评议会 抗真菌肽和其使用方法
US9399675B2 (en) 2007-02-28 2016-07-26 The Board Of Regents Of The University Of Oklahoma Methods and compositions for diagnosing Alzheimer's disease and age-related macular degeneration
WO2011103567A2 (en) 2010-02-22 2011-08-25 Los Angeles Biomedical Research Institute At Harbor-Ucla Medical Center Peptides and methods for inducing cell death
CA2797033C (en) 2010-04-22 2021-10-19 Longevity Biotech, Inc. Highly active polypeptides and methods of making and using the same

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
PEREIRA ET AL., "CAP37, a neutrophil granule-derived protein stimulates protein kinase C activity in endothelial cells", JOURNAL OF LEUKOCYTE BIOLOGY, (199609), vol. 60, pages 415 - 422 *

Also Published As

Publication number Publication date
US9603896B2 (en) 2017-03-28
CA2893504A1 (en) 2014-06-12
WO2014089088A1 (en) 2014-06-12
DK2925341T3 (en) 2018-05-07
EP2925341B1 (en) 2018-01-31
EP2925341A4 (en) 2016-10-05
US20150374785A1 (en) 2015-12-31
CA2893504C (en) 2016-11-22
AU2013355391A1 (en) 2015-07-23
EP2925341A1 (en) 2015-10-07
US20160317617A1 (en) 2016-11-03
JP6377070B2 (ja) 2018-08-22
JP2016501889A (ja) 2016-01-21

Similar Documents

Publication Publication Date Title
US20160317617A1 (en) Peptide Compounds and Methods of Production and Use Thereof
US9862748B2 (en) Peptide compounds and methods of production and use thereof
JP2023539476A (ja) アネキシンa1のn末端ペプチド製剤及び方法
AU2018249816B2 (en) Mineral coated microparticles for sustained delivery of biologically active molecules
US20180208633A1 (en) Peptide Compounds and Methods of Production and Use Thereof
EP3802568A1 (en) Peptide therapeutics for treating alzheimer's disease and related conditions
JP2016501889A5 (cg-RX-API-DMAC7.html)
US11884710B2 (en) Peptide compounds and methods of use in wound healing
JP6042106B2 (ja) メチオニン・スルホキシドを含む新規ポリペプチド
AU2006275417B2 (en) Antifungal peptides and methods of use thereof
KR102609115B1 (ko) 펩타이드를 포함하는 안구 질환의 치료용 조성물
WO2024064288A1 (en) Tlr4 inhibitors for cancer treatment

Legal Events

Date Code Title Description
DA3 Amendments made section 104

Free format text: THE NATURE OF THE AMENDMENT IS: AMEND THE NAME OF THE INVENTOR TO READ PEREIRA, H. ANNE; KASUS-JACOBI, ANNE AND GRIFFITH, GINA L.

FGA Letters patent sealed or granted (standard patent)